✨

Peptides — Cosmetic Actives, GLP-1 APIs & Research-Grade Factory Sourcing (No MOQ)

Bioactive cosmetic peptides, GLP-1/metabolic peptide APIs, personalised-therapy actives, and research-grade raw powders sourced from Shanghai, Jiangsu, Xi'an, and Chengdu certified clusters. Market context: global peptides valued at **USD 21.4B (2022), 10.2% CAGR → 2030**; synthesis submarket USD 6.18B (2025) → **USD 9.91B (2030)**. ICH + NMPA + ISO-aligned manufacturers incl. tier-1 100,000 sqm cGMP houses. Both SPPS + FPPS scalable capacity. Sinorce guarantees: GMP vendor vetting, batch-specific independent CoA, HS-code export compliance, cold-chain logistics, No MOQ.

Executive Summary — Why Source Peptides Now

The **global peptide market** was valued at approximately **USD 21.4 billion in 2022** and is projected to expand at a robust **10.2% CAGR through 2030**, driven by breakthroughs in targeted therapeutics, anti-ageing cosmetics, and biomedical R&D.
The **peptide synthesis submarket specifically** — our core sourcing focus — stood at **USD 6.18B in 2025** and is forecast to reach **USD 9.91B by 2030** (Business Research Company data).
Demand outpaces traditional supply chains, so the ability to source high-purity, rigorously tested peptides from compliant, scalable manufacturers has become a competitive advantage.
Sinorce bridges the gap between world-class Chinese manufacturing and global quality standards — delivering reliability, transparency, and excellence.

Key Market Drivers — Four Tailwinds Powering Demand

**The GLP-1 and Metabolic Therapeutics Boom:** Peptide-based treatments for diabetes and weight management (e.g., semaglutide, tirzepatide, retatrutide) have created massive, sustained global demand for high-quality peptide APIs and research-grade compounds — suppliers are already scaling generic SPPS production in preparation for post-patent expiry windows.
**Advanced Cosmetic & Dermatological Applications:** Bioactive peptides (copper peptides, signal peptides, neurotransmitter-inhibitor peptides) are increasingly demanded by the global skincare industry for their clinically demonstrated efficacy in collagen synthesis, anti-wrinkle, skin-repair, and brightening formulations — driving a surge in cosmetic-grade peptide sourcing.
**Expansion of Biomedical Research:** Universities, CROs (Contract Research Organizations), and biotech startups require highly pure, custom-synthesized peptides for drug discovery, proteomics, antibody development, and vaccine R&D — with "no MOQ" milligram-to-gram order flexibility being a critical commercial differentiator.
**Shift Toward Targeted Therapies:** Peptides offer the unique advantage of high target specificity and low systemic toxicity compared to traditional small-molecule drugs, making them the preferred modality for next-generation pharma development and the backbone of the personalized-medicine pipeline.

Strategic China Manufacturing Advantage — SPPS + FPPS Scalable Capacity

**Scalable Synthesis Capabilities:** Leading Chinese manufacturers have heavily invested in both **Solid-Phase Peptide Synthesis (SPPS)** for high-purity custom/mid-scale runs AND **Fluid/Liquid-Phase Peptide Synthesis (FPPS)** for cost-effective large-batch (kg–tonne scale) commercial production — enabling seamless scaling from milligram-level R&D samples to multi-kilogram finished-goods campaigns.
**Cost Efficiency Without Compromising Quality:** Advanced infrastructure, vertically integrated raw-amino-acid supply chains, and deep engineering expertise in the **Guangzhou, Shanghai, Jiangsu, Xi'an, and Chengdu** industrial clusters allow for highly competitive FOB pricing while maintaining strict ICH-grade quality standards. Regional analysis estimates China accounts for ~60% of global peptide synthesis capacity.
**Growing Domestic Regulatory Alignment:** Top-tier Chinese peptide manufacturers — exemplified by **tier-1 cGMP campuses (26+ years, 100,000 sqm capacity)** — are increasingly aligned with **ICH (International Council for Harmonisation)** Q7 guidelines and hold **NMPA** plus international **GMP** certifications (ISO 9001, ISO 13485, ISO 22716 for cosmetic-grade lines), ensuring outputs meet EU/USA/APAC export requirements.
**Cluster advantage:** Shanghai/Jiangsu (API-grade SPPS + FPPS bulk), Xi'an (cosmetic-grade actives + natural peptides), Guangzhou/Chengdu (finished cosmetic formulation + private-label OEM). Sinorce pre-vets manufacturers within these clusters so buyers avoid the low-end "wild west" of uncertified traders.

🧴 Lane 1 — Cosmetic Peptide Actives (Top Export SKUs)

Copper Tripeptide-1 (GHK-Cu): 99% HPLC pure, blue powder or pre-diluted 1% in water / hyaluronic acid solution — hair regrowth, skin repair, anti-wrinkle actives
Palmitoyl Tripeptide-1 / -3, Palmitoyl Pentapeptide-4: 98%+ lyophilised — collagen / elastin stimulation for anti-wrinkle serums
Acetyl Hexapeptide-8: 98%+ lyophilised — topical wrinkle smoothing for serums, eye creams, masks
Oligopeptide-1 / -2 / -6: epidermal repair, post-procedure soothing, brightening formulations
Carnosine (β-alanyl-L-histidine): 99% HPLC — anti-glycation, antioxidant, for anti-ageing moisturisers
L-Glutathione (reduced GSH): 98%+ HPLC / titration — skin brightening, tone evening, for serums, masks, and oral nutraceuticals
Nonapeptide-1 (Melanostatin class): melanin modulation, skin-tone evenness — whitening / brightening serums
Hydrolysed Silk / Silk Peptides: 90% protein (Kjeldahl) — moisture, barrier repair, for toners, essences, sheet masks

🧪 Lane 2 — Research-Grade Raw Materials (Formulation / Licensed Labs)

Growth-hormone secretagogue blends: CJC-1295 No DAC + Ipamorelin, CJC-1295 DAC, Hexarelin, GHRP-2, GHRP-6, MK-677 (Ibutamoren)
Tissue / injury recovery: BPC-157 (acetate), TB-500 (Thymosin β-4 fragment)
Skin / tan / libido: Melanotan II, PT-141 (Bremelanotide)
Metabolic / weight-management raw powders (post-2026 patent expiry): Semaglutide, Tirzepatide, Retatrutide — suppliers already scaling generic SPPS production
Anti-ageing / longevity research: Epitalon, Thymosin Alpha-1, MOTS-C
Nootropic / cognitive research peptides: Selank, Semax, DSIP, Pinealon
HGH Fragment 176–191 (AOD-9604)
All SKUs framed as raw materials for licensed research labs, formulation chemists, and authorised importers. Standard industry "for research use only, not for human administration" disclaimer applied on packaging.

🇺🇸 USA & North America — Regulatory Paths

Cosmetic lane (cleanest): FDA MoCRA 2022 compliance — Facility Registration (2-yr renewal), Product Listing per SKU, Safety Substantiation (毒理/临床/文献证据), Adverse Event Reporting (15-day SAE). New actives: INCI name required; VCRP Voluntary Registration Program encouraged.
Cosmetic lane — new ingredient steps: apply for INCI (INC committee 3–6 months, 5 meetings/yr Feb/Apr/Jun/Sep/Nov) → compile CIR safety review → MoCRA listing + US Responsible Person designation
Research-grade lane: supply to licensed compounding pharmacies, research institutions, authorised importers with WDA-style wholesale authorisation. Non-DTC, non-therapeutic-claim framing is the standard industry model used by all top-tier Chinese peptide suppliers.
Dangerous-goods classification: Non-DG (IATA / IMDG) for nearly all cosmetic peptides — ship with Non-DG letter, proper UN classification, and MSDS

🇪🇺 EU + UK — Regulatory Paths

Cosmetic lane (cleanest): EU Regulation 1223/2009 full compliance. ① Appoint EU/UK Responsible Person (RP); ② Commission a qualified safety assessor to write **CPSR (Cosmetic Product Safety Report)** Part A + Part B; ③ Compile **PIF (Product Information File)** 14-section technical dossier including formula CAS#, GMP certificate, stability data, claims evidence; ④ Notify CPNP (EU) / SCPN (UK) before product launch; ⑤ Factory must pass **ISO 22716 Cosmetic GMP audit** (mandatory for market access).
New cosmetic peptides: REACH registration if >1 t/yr volume thresholds triggered; dossiers can be prepared in parallel with INCI.
Research-grade lane: wholesale import into EU/UK requires **WDA (Wholesale Dealer Authorisation)** from MHRA (UK) or national competent authority (EU member states). "For research use only" is not a defence against enforcement for materials classified as medicines by default (MHRA Guidance Note 8 / EU EudraLex Vol. 2 / CMDh classification rules apply).
Power supply for cardo equipment: N/A (peptides do not require CE marking — common misconception; CE applies to electrical/medical devices, not cosmetics or raw chemical powders)

🌏 Asia, GCC, and Middle East — Regulatory Paths

ASEAN 6: ASEAN Cosmetic Directive (ACD) — common ISO 22716 GMP + country-specific product notification (Indonesia BPOM, Thailand FDA, Philippines FDA, Malaysia NPRA, Vietnam DAV, Singapore HSA)
Japan + Korea: Japan PMDA Pharmaceutical & Cosmetics Act (quasi-drug 医药部外品 classification if making active claims, general cosmetics if not). Korea MFDS functional cosmetics report system.
China domestic re-export: NMPA Cosmetic New Ingredient Notification (化妆品新原料备案, 3-year monitoring period) for novel peptides sold in China domestic.
GCC (KSA, UAE, Qatar, Bahrain, Kuwait, Oman): SFDA (KSA) Cosmetic Registration + SASO GSO 2489 = ISO 22716 GMP audit. ESMA (UAE) notification. **Halal certification (JAKIM / IFANCA)** is a commercial requirement for retail cosmetics in all GCC markets and is strongly recommended.
India / South Asia: BIS CR (Compulsory Registration) when applicable; India CDSCO cosmetic import registration.
Cleanest B2B route for "research-grade" materials in SE Asia/GCC: licensed-lab and Dubai free-zone importers, not end-user DTC.

Standard Specification & QC Checklist

Purity: Cosmetic peptides 98.0–99.0%+ (HPLC area-% corrected, gradient elution, peak-identification by retention time + DAD). Research-grade typically 99.0–99.5%+.
Identity: LC-MS / ESI-QToF confirm molecular mass ±0.2 Da of theoretical. Amino acid analysis (AAA) confirms sequence stoichiometry. NMR (400 MHz) available on new or custom sequences for structure proof.
Impurity & residual: residual TFA ≤0.1% (ion chromatography), residual solvents ICH Q3C Class 1/2/3 limits, moisture (KF titration), acetate counter-ion content by HPLC/elemental analysis, heavy metals Pb/As/Cd/Hg ≤10 ppm (USP <232>).
Microbial: USP <61> Total Aerobic Count ≤100 CFU/g, <62> Yeast/Mould ≤10 CFU/g, absence of S. aureus, P. aeruginosa, E. coli, C. albicans for cosmetic grade. Endotoxin LAL <0.25 EU/mg for research/injectable-grade.
Physical: Appearance (colour test vs reference standard), particle size distribution (Malvern Mastersizer if required), pH of 1% w/w aqueous solution (±0.3 tolerance), solubility in declared solvents (water, acetic acid, ethanol).
Packaging-grade check: amber type III glass vials / HDPE / PET, nitrogen-flush, desiccant pouch (montmorillonite or molecular sieve 4Å), tamper-evident aluminium foil induction seal, lot + expiry laser-mark on cap + side.

Sinorce Commitments — Vendor Vetting, Documentation & Cold-Chain Assurance

**Rigorous Vendor Vetting (pre-booking audit):** We partner exclusively with manufacturers who hold verifiable cGMP / ISO 9001 / ISO 22716 certifications and maintain ISO-class cleanrooms (ISO 7 / Class 10,000 minimum for SPPS + lyophilisation areas). Audit scope covers: gowning/airlock/decontamination SOPs, HPLC fleet count (50–200+ systems) + in-house LC-MS fleet (≥5 for reputable tier-1 houses), traceability matrix (lot no. links raw amino-acid batch → synthesis log → purification run → CoA → shipment), and real-time + accelerated stability-study data.
**Transparent Documentation, batch-specific:** Every shipment is backed by comprehensive, batch-specific documentation including **Certificates of Analysis (CoA)** from independent 3rd-party accredited peptide-testing laboratories (EU or international; we coordinate retests on 2% of vials, buyer-funded with full chain-of-custody handled), **MSDS** (16 sections per GHS), TSE/BSE-free declaration, allergen-free declaration, and Non-GMO statement plus WADA 2025 Prohibited List residual-screening certificate if required for EU.
**Regulatory Navigation & Export Compliance:** Our team handles proper **HS code classification** (3822 / 3001 / 2934 series as applicable per SKU), Non-DG classification letters where applicable, and full export documentation — minimizing the risk of customs delays or seizures at destination for USA, EU, UK, GCC, and APAC lanes.
**Cold-Chain Logistics Expertise:** We coordinate with specialized freight forwarders to ensure temperature-sensitive products ship with appropriate thermal packaging (2–8°C cool packs, PCM phase-change materials, dry ice for -20°C injectable-grade if required) and electronic data loggers (±0.3°C accuracy, full temperature curve supplied on delivery). Lyophilised cosmetic peptides are ambient-stable up to 30 days; cool-chain is standard for high-value SKUs or >60-day combined air/sea lanes.
**Independent 3rd-lab verification option:** Buyers may elect spot-testing on any lot; we coordinate sample handoff, chain-of-custody paperwork, and side-by-side comparison against manufacturer in-house CoA data.
**Every lot is QC-photographed** before pallet leaves the factory, with video inspections available on any order ≥25kg of raw powder or ≥5,000 finished units.

OEM / Private Label & Custom Synthesis Options

Cosmetic finished goods: 10–500ppm pre-formulated serums, ampoules, essences, toners, sheet masks in your brand — artwork/DIELINE handoff → Pantone colour match → stability test batch → full production run → CPSR/PIF compilation support → retail carton labelling per INCI list.
Raw active packaging: custom branded amber vials (silk-screen, pad-print, or laser-etched), custom lot number format, multi-language labels (EN+DE+FR+IT+ES+AR on request), tamper-evident shrink sleeve, EU/USA bilingual IFUs.
Custom peptide synthesis (CPS / SPPS): modified peptides (biotinylation, phosphorylation, fluorescent tags, PEGylation, disulfide bridges, cyclic peptides, peptidomimetics) — quoted per sequence length, purity grade, and quantity. Typical 4–8 weeks from PO to QC.
Patent-sensitive SKUs: Semaglutide / Tirzepatide / Retatrutide generic SPPS — we connect buyers with suppliers offering non-infringing process patents or post-expiry commercial supply, with legal opinion where buyer requests it.

Packaging, Cold Chain, Shipping & No-MOQ Terms

Raw active vials: 10mg / 50mg / 100mg / 500mg / 1g / 5g / 10g / 50g / 100g / 1kg typical SKU sizes. Amber glass (lyophilised powder), or food-grade HDPE (≥500g bulk powder). Aluminium foil pouches with internal PE liner for powder kegs (≥5kg).
Finished cosmetics: retail glass/plastic dropper bottles, ampoules, pump bottles — blister or tray insert in folding carton → master carton with barcode/UPC/FNSKU labels as required → 24–48 cartons per pallet, stretch wrap + corner protectors.
Cold-chain handling: 2–8°C cool-pack for high-value actives; electronic data logger (±0.3°C accuracy) included. IATA Non-DG declaration + MSDS + Non-animal / TSE-free certificate + allergen-free declaration in every shipping pouch.
Freight: air express (DHL/UPS/FedEx for ≤50kg pilots), air freight (≥50kg), sea freight LCL/ FCL (≥200kg commercial). We coordinate Incoterms EXW / FOB Shanghai / CIF destination per buyer.
No MOQ terms: 50g pilot batches available (priced at small-batch premium), 1–5kg development batches at standard rates, 100kg+ commercial container batches at contracted FOB rates. 100% QC photographed before pallet leaves factory, video inspection available on any order ≥25kg.
**2030 Future Outlook & Pipeline:** As we move toward 2030, the peptide market will continue to innovate with a strong focus on **oral peptide delivery systems**, **peptide-drug conjugates (PDCs)**, and **green / sustainable manufacturing practices** (reduced solvent consumption, amino-acid circular recovery). Companies that secure reliable, high-quality supply chains today will be positioned to capitalize on tomorrow's breakthroughs.
**Secure your supply chain with confidence** — contact Sinorce for vendor pre-qualification, batch-specific CoA samples, HS-code classification, and a no-obligation FOB quote for your next cosmetic, research, or therapeutic peptide campaign.

Back to Showcases Request a Supplier Shortlist